Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug ,docarpamine

References

• Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome. Fertil Steril 1978;30:255–68
   PubMed Web of Science ®Google Scholar
• Haning RU, Strawn EV, Nolten WE. Patho-physiology of the ovarian hyperstimulation syn-drome. Obstet Gynecol 1989;66:220–4
   Google Scholar
• Navot D, Margalioth EJ, Laufer N, et al. Direct correlation between plasma rennin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 1987;40:57–61
   Google Scholar
• Meldrum DR, Wisot A, Hamilton F, et al. Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval. Fertil Steril 1989; 51:455–9
   PubMed Web of Science ®Google Scholar
• Brinsden PR, Wada I, Tan SL, et al. Diagnosis, prevention and management of ovarian hyper-stimulation syndrome. Br J Obstet Gynaecol 1995; 102:767–72
   PubMedGoogle Scholar
• Ferraretti AP, Gianaroli L, Diotallevi L, et al. Dopa-mine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 1992;7:180–3
   Google Scholar
• Navot D, Bergh PA, Laufer N. Ovarian hyper-stimulation syndrome in novel reproductive techno-logies: prevention and treatment. Fertil Steril 1992; 58:249–61
   Google Scholar
• Morris RS, Miller C, Jacobs L, et al. Conservative management of ovarian hyperstimulation syndrome. J Reprod Med 1995;40:711–14
   Google Scholar
• Thaler I, Yoffe N, Kaftory JK, et al. Treatment of ovarian hyperstimulation syndrome: the physiologic basis for a modified approach. Fertil Steril 1981; 36:110–13
   PubMed Web of Science ®Google Scholar
• Borenstein R, Elhalah U, Lunenfeld B, et al. Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach. Fertil Steril 1989;51:791–5
   PubMed Web of Science ®Google Scholar
• Aboulghar MA, Mansour RT, Serour GI, et al. Ultra-sonically guided vaginal aspiration of ascites in the treatment of severe ovarian hyperstimulation syn-drome. Fertil Steril 1990;53:933–5
   PubMed Web of Science ®Google Scholar
• McDonald RH, Goldberg LI, McNay JL, et al. Effect of dopamine in man: augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow. J Clin Invest 1964;43:1116–24
   PubMed Web of Science ®Google Scholar
• Goldberg LI. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev 1972;24:1–29
   PubMed Web of Science ®Google Scholar
• Yoshikawa M, Endo H, Otsuka M. Comparative study of the disposition of a new orally active dopa-mine prodrug, N-(N-acetyl-L-methiony1)-0, 0-his (ethoxycarbonyl) dopamine (TA-870) and dopamine hydrochloride in rats and dogs. Drug Metab Dispos 1988;16: 754–8
   Google Scholar
• Yoshikawa M, Endo H, Komatsu K. Disposition of a new orally active dopamine prodrug, N-(N-acetyl- L-methiony1)-0, 0-bis (ethoxycarbonyl) dopamine (TA-870) in humans. Drug Metab Dispos 1990; 18:212–17
   Google Scholar
• Yamaguchi I, Nishiyama S, Akimoto Y, et al. A novel orally active dopamine prodrug TA-870. I. Renal and cardiovascular effects and plasma levels of free dopamine in dogs and rats. J Cardiovasc Pharmacol 1989;13:879–86
   Google Scholar
• Orvieto R, Ben-Rafael Z. Role of intravenous albumin in the prevention of severe ovarian hyper-stimulation syndrome. Hum Reprod 1998;13: 3306–9
   Google Scholar
• Medical Research International, Society for Assisted Reproductive Technology (SART), The American Fertility Society. In vitro fertilization—embryo transfer (IVF-ET) in the United States: 1990 results from the IVF-ET registry. Fertil Steril 1992;57: 15–24
   Google Scholar
• Aboulghar MA, Mansour RT, Serour GI, et al. Auto-transfusion of the ascitic fluid in the treatment of severe ovarian hyperstimulation syndrome. Fertil Steril 1992;58:1056–9
   Google Scholar
• Fukaya T, Chida S, Terada Y, et al. Treatment of severe ovarian hyperstimulation syndrome by ultrafiltration and reinfusion of ascitic fluid. Fertil Steril 1994;61:561–4
   Google Scholar
• Koike T, Araki S, Minakami H, et al. Clinical efficacy of peritoneovenous shunting for the treatment of severe ovarian hyperstimulation syndrome. Hum Reprod 2000;15:113–17
   PubMedGoogle Scholar
• Takamizawa S, Shibahara H, Taneichi A, et al. Dynamic changes of the immunoglobulins in patients with severe ovarian hyperstimulation syndrome: efficacy of a novel treatment using peritoneo-venous shunt. Am J Reprod Immunol 2002;47:25–30
   PubMedGoogle Scholar
• MatsubayashiK, Ueda Y, Ogino H, et al. Oral admin-istration of the dopamine prodrug docarpamine shortens need for drip infusion of dopamine in patients with low cardiac output syndrome after cardiac surgery. Thorac Cardiovasc Surg 1999;47: 352–6
   Google Scholar
• Watarida S, Shiraishi S, Sugita T, et al. Effects of docarpamine on hemodynamics after open heart surgery in children. Ann Thorac Cardiovasc Surg 2000;6:106–9
   Google Scholar
• Funasaki T, Tsutumi M, Takase S, et al. Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. Am J Gastroenterol 1999;94:2475–81
   Google Scholar
• Ogawa H, Kusukawa M, Matsui S. Clinical efficacy of TA-870, a new oral dopamine in patients with tapering of dopamine: multiclinical co-operative study [in Japanese]. Yakuritochiryo 1991;19: 1907–31
   Google Scholar